Stock Worth Mentioning Today: Could Delcath Systems, Inc. See a Reversal After This Very Weak Session?

Stock Worth Mentioning Today: Could Delcath Systems, Inc. See a Reversal After This Very Weak Session?

The stock of Delcath Systems, Inc. (NASDAQ:DCTH) is a huge mover today! About 128,504 shares traded hands. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 60.11% since April 18, 2016 and is downtrending. It has underperformed by 64.54% the S&P500.
The move comes after 6 months negative chart setup for the $4.61M company. It was reported on Nov, 18 by Barchart.com. We have $1.89 PT which if reached, will make NASDAQ:DCTH worth $507,100 less.

According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”

Insitutional Activity: The institutional sentiment decreased to 0 in 2016 Q2. Its down 1.13, from 1.13 in 2016Q1. The ratio dropped, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
National Bank Of America De accumulated 0% or 4,604 shares. Creative Planning accumulated 0% or 307 shares. Wells Fargo Mn owns 157 shares or 0% of their US portfolio. Private Advisor Gp Ltd Com accumulated 206,670 shares or 0% of the stock. Moreover, Geode Capital Management Ltd Liability Corporation has 0% invested in Delcath Systems, Inc. (NASDAQ:DCTH) for 39,792 shares. Renaissance Technology Ltd Liability Corp last reported 754,998 shares in the company. Ladenburg Thalmann Fincl Svcs Inc has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). The Ontario – Canada-based Royal National Bank Of Canada has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Goldman Sachs Grp Inc Incorporated holds 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH) for 15,211 shares. Blackrock Institutional Tru Com Na holds 0% or 531,871 shares in its portfolio. Vanguard Gru Inc accumulated 77,988 shares or 0% of the stock. Blackrock Fund Advsr has 4,024 shares for 0% of their US portfolio. Susquehanna Gp Llp has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Gp One Trading Ltd Partnership last reported 0% of its portfolio in the stock. Deutsche Bancshares Ag owns 5 shares or 0% of their US portfolio.

More news for Delcath Systems, Inc. (NASDAQ:DCTH) were recently published by: Prnewswire.com, which released: “Delcath Announces Third Quarter Financial Results” on November 11, 2016. Marketwatch.com‘s article titled: “Delcath Systems Inc.” and published on December 22, 2009 is yet another important article.

DCTH Company Profile

Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment